Information Provided By:
Fly News Breaks for February 11, 2019
KMB
Feb 11, 2019 | 12:20 EDT
Exane BNP Paribas analyst Jeff Stent initiated Kimberly-Clark with an Outperform rating and $130 price target, stating that while the company faces structural challenges "if ever there is a time to buy, it is now" as the input cost picture improves and industry pricing is "starting to kick in."
News For KMB From the Last 2 Days
KMB
Mar 27, 2024 | 16:24 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
KMB
Mar 27, 2024 | 12:00 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here
KMB
Mar 27, 2024 | 07:10 EDT
Consensus $6.89. The company noted that the outlook it provided in January is consistent with its new long-term growth and return targets. The company continues to expect to deliver a low-to-mid single-digit percentage increase in 2024 organic net sales versus the prior year period, with growth in reported net sales forecast to reflect negative impacts of approximately 300 basis points from currency translation and 60 basis points from the Brazil Tissue divestiture. Adjusted operating profit is still expected to grow at a high single-digit to low double-digit rate on a constant-currency basis and adjusted earnings per share are expected to grow at a high single-digit rate on a constant-currency basis versus the prior year period. Reported growth in operating profit and earnings per share are still expected to be negatively impacted by approximately 400 basis points from currency translation. This outlook reflects assumptions subject to change given the macro environment.